Ecolab AI Stock Analysis
Want to see ECL full AI Analyst Report?
Ecolab (ECL) AI Stock Analysis
Ecolab
(NYSE:ECL)
The score is driven primarily by improving profitability and a constructive earnings outlook with clear 2027 growth and margin commitments. Offsetting factors include increased leverage and some weakening cash-flow conversion, while technicals show an extended run (overbought signals) and valuation is rich at ~40.6x earnings with only ~1% yield support.
Ecolab Key Performance Indicators (KPIs)
Operating Income by SegmentShows profitability across different business units, highlighting which segments drive earnings and where there might be challenges or opportunities for growth.
Ecolab’s operating‑income mix has clearly shifted toward Institutional & Specialty, which shows sustained, accelerating profit contribution into 2026 while legacy Industrial, Healthcare and Other drop to zero after 2024—indicating a reporting/portfolio consolidation into higher‑margin businesses. This matches management’s pivot (Life Sciences, Digital, Global High‑Tech) and their 20% OI margin target, but watch noisy one‑offs (notably a large corporate swing in 2024Q3) and near‑term margin headwinds from commodity inflation and acquisition costs that could obscure organic progress.
Ecolab (ECL) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $86.29B
- Dividend Yield
- 0.95%
- Average Volume (3M)
- 1.44M
- Price to Earnings (P/E)
- 41.5
- Beta (1Y)
- 0.48
- Revenue Growth
- 9.33%
- EPS Growth
- 5.71%
- Country
- US
- Employees
- 48,000
- Sector
- Basic Materials
- Sector Strength
- 61
- Industry
- Chemicals - Specialty
Ecolab Business Overview & Revenue Model
Company Description
Ecolab Inc. provides water, hygiene, and infection prevention solutions and services in the United States and internationally. The company operates through four segments: Global Water, Global Institutional & Specialty, Global Pest Elimination, and Gl...
How the Company Makes Money
Ecolab primarily makes money by selling specialized consumable products (notably cleaning and sanitation chemicals, water treatment chemicals, and related formulations) bundled with service programs and, in many cases, equipment that dispenses, monit...
Ecolab Earnings Call Summary
The call was strongly positive. Ecolab reported accelerating organic sales and operating income growth, broad-based business outperformance, strong momentum in Life Sciences, Digital, Pest and Global High-Tech, and confidence in achieving its 2027 growth and margin commitments. The principal challenges were persistent commodity inflation, a declining Institutional market, Middle East-related headwinds, M&A-related amortization and interest costs, and variability in near-term margins and High-Tech quarterly growth.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2027, Ecolab expects organic sales growth at the upper end of its 5% to 7% target, adjusted operating income margin to reach the 20%, and adjusted EPS growth to meet or exceed its long-term adjusted EPS growth target of 12% to 15%; underlying earnings growth is expected to be mid-teens type of growth, with roughly 5 percentage point headwind in the first half and a 5 percentage point tailwind in the second half, while first-half volume is expected to be 1% to 2% and pricing 5% to 6%, followed by second-half volume of 2% to 3% and pricing a bit lower. Life Sciences is expected to deliver 10% to 12% top line growth and reach 30% operating income margin in the next few years; Global High-Tech is expected to grow more than 25% annually, reach $4 billion in sales by 2030 and deliver 25% operating income margin; pricing is expected to remain 5% to 6% through the fourth quarter and probably the first half of next year, while DPC is assumed to stay at a high level till the end of next year.
Ecolab Financial Statement Overview
Summary
Strong and improving profitability (TTM net margin ~12% vs ~7.7% in 2022; EBIT margin ~16.8% vs ~11.3%), supporting high-quality earnings. Offsets include materially higher leverage (debt-to-equity ~1.32 TTM vs ~0.97 in 2025) and softer cash-flow durability (FCF ~59% of net income with TTM FCF down ~4.2%), plus slower recent top-line growth (~3.1% TTM).
Income Statement
82Very PositiveBalance Sheet
62PositiveCash Flow
67Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.37B | 16.08B | 15.74B | 15.32B | 14.19B | 12.73B |
| Gross Profit | 7.63B | 7.16B | 6.84B | 6.18B | 5.42B | 5.22B |
| EBITDA | 3.63B | 3.46B | 3.85B | 3.03B | 2.55B | 2.47B |
| Net Income | 2.08B | 2.08B | 2.11B | 1.37B | 1.09B | 1.13B |
Balance Sheet | ||||||
| Total Assets | 31.11B | 24.70B | 22.39B | 21.85B | 21.46B | 21.21B |
| Cash, Cash Equivalents and Short-Term Investments | 722.30M | 646.20M | 1.26B | 919.50M | 598.60M | 359.90M |
| Total Debt | 13.77B | 9.43B | 8.28B | 8.73B | 9.03B | 9.16B |
| Total Liabilities | 20.65B | 14.89B | 13.60B | 13.77B | 14.21B | 13.95B |
| Stockholders Equity | 10.42B | 9.77B | 8.76B | 8.04B | 7.24B | 7.22B |
Cash Flow | ||||||
| Free Cash Flow | 1.80B | 1.90B | 1.82B | 1.64B | 1.08B | 1.42B |
| Operating Cash Flow | 3.03B | 2.95B | 2.81B | 2.41B | 1.79B | 2.06B |
| Investing Cash Flow | -7.60B | -2.71B | -433.80M | -990.50M | -716.80M | -4.58B |
| Financing Cash Flow | 3.32B | -853.30M | -2.02B | -1.05B | -837.30M | 1.60B |
Ecolab Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ECL, the sentiment is Positive. The current price of 307.86 is above the 20-day moving average (MA) of 297.72, above the 50-day MA of 285.25, and above the 200-day MA of 275.97, indicating a bullish trend. The MACD of 6.65 indicates Negative momentum. The RSI at 62.47 is Neutral, neither overbought nor oversold. The STOCH value of 53.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ECL.
Ecolab Risk Analysis
Ecolab disclosed 24 risk factors in its most recent earnings report. Ecolab reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksEcolab Peers Comparison
Overall Rating
IOSP72Outperform
ECL70Outperform
HWKN69Neutral
ASH61Neutral
KWR60Neutral
SCL55Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | $1.91B | 13.78 | 10.42% | 2.29% | 4.73% | ― | |
| 70Outperform | $85.83B | 41.52 | 20.70% | 0.95% | 9.33% | 5.71% | |
| 69Neutral | $3.18B | 36.75 | 15.86% | 0.51% | 9.02% | 3.18% | |
| Sector * | 61Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
| 61Neutral | $3.52B | 852.44 | 0.21% | 2.18% | 2.08% | ― | |
| 60Neutral | $2.65B | 27.74 | 7.02% | 1.32% | 8.68% | ― | |
| 55Neutral | $1.52B | 347.05 | 0.36% | 2.40% | 10.02% | -90.50% |
* Basic Materials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ECL | Ecolab | 307.86 | 48.71 | 18.80% | |
| ASH | Ashland Global Holdings, Inc. | 76.72 | 25.06 | 48.52% | |
| HWKN | Hawkins Inc | 152.13 | 25.25 | 19.90% | |
| IOSP | Innospec | 78.29 | 4.42 | 5.98% | |
| KWR | Quaker Chemical | 155.91 | 22.35 | 16.74% | |
| SCL | Stepan Company | 65.94 | 22.68 | 52.44% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026
